The DRSN research centers (U54) conduct preclinical research focused on innovative strategies to understand and combat mechanisms of tumor resistance (intrinsic or acquired) and/or to exploit tumor sensitivity to anti-cancer therapies. These strategies explore genetic and other molecular characteristics of the cancer underlying sensitivity/resistance to anticancer treatments.

Preclinical discoveries resulting from research performed by DRSN research centers are expected to enable future clinical application of concepts to prevent and/or overcome cancer drug resistance within the NCI Cancer Therapy Evaluation Program (CTEP) clinical trials networks.